Countries Austria Iran Brazil Israel Bulgaria Italy Canada - PowerPoint PPT Presentation

Countries Austria Iran Brazil Israel Bulgaria Italy Canada Japan Chile Kenya China Mexico Colombia New Zealand Germany Netherlands Dominican Republic Pakistan Finland Peru Great Britain Philippines Guatemala Singapore Hungary Switzerland India United States (2)

Topics ranked in terms of importance when other non-rank responses are factored in *Other: Shared decision making/patient participation, Best practices to follow

25 22 20 15 10 7 5 0 Yes No

Yes: Italy, Austria, Switzerland, Germany, China, Great Britain, Netherlands No: United States (2), Hungary, Kenya, India, Guatemala, Chile, Israel, Finland, Mexico, Canada, Brazil, Dominican Republic, Colombia, Peru, New Zealand, Philippines, Iran, Singapore, Bulgaria, Japan, Pakistan

OTHER 6 PERUSE A LIST PROVIDED IN YOUR OR ANOTHER ORGANIZATIONS' 12 WEBSITE THEY CONTACT YOUR ORGANIZATION BY PHONE OR EMAIL FOR A 16 RECOMMENDATION THEIR PRIMARY DOCTOR WILL TRIAGE THEM TO A CANCER CENTER 19 0 2 4 6 8 10 12 14 16 18 20

19 13 12 8 5 4 DISTANCE FINANCIAL/HEALTH PERSONAL AND FEAR OF OFFENDING LACK OF GIST *OTHER INSURANCE CULTURAL BELIEFS CURRENT PHYSICIAN SPECIALISTS *Other: Family physicians, Patients do not know availability, Health insurance, Ignorance of importance of treatment in specialized center

25 20 20 15 13 10 10 7 7 7 5 6 4 3 3 0 1 0 Easily accessible Somewhat accessible Not easily accessible Not at all accessible Imatinib as 1st line treatment Sunitinib as 2nd line treatment Regorafenib as 3rd line treatment

Not easily accessible Imatinib : Peru, Philippines, Pakistan Sunitinib : Chile, Dominican Republic, Peru, Philippines, Iran, Singapore, Pakistan Regorafenib : Kenya, Germany, China, Dominican Republic, Singapore, Pakistan Not at all accessible Sunitinib: Guatemala Regorafenib: India, Guatemala, Mexico, Colombia, Philippines, Iran, Great Britain

15 14 12 9 9 8 7 6 5 5 5 4 4 3 1 1 TOTALLY REIMBURSABLE SOMEWHAT REIMBURSABLE NOT EASILY REIMBURSABLE NOT AT ALL REIMBURSABLE Imatinib - Adjuvant Imatinib-metastatic/recurrent disease Sunitinib Regorafenib

Not easily reimbursable Imatinib – Adjuvant: Hungary Imatinib – Metastatic: Peru Sunitinib: Chile, Dominican Republic, Peru Regorafenib: Germany, China, Chile, Dominican Republic Not at all reimbursable Imatinib – Adjuvant: Kenya, India, Iran, Singapore, Pakistan Imatinib – Metastatic: India, Iran, Singapore, Pakist an Sunitinib : India, Philippines, Iran, Singapore, Pakistan Regorafenib: India, Mexico, Colombia, Philippines, Iran, Singapore, Bulgaria, Pakistan

DO NOT HAVE ACCESS AT ALL 6 DO NOT HAVE EASY ACCESS 15 HAVE SOMEWHAT EASY ACCESS 2 HAVE VERY EASY ACCESS 4 0 2 4 6 8 10 12 14 16

Have Very Easy Access: United States, Israel, Brazil, Netherlands Have Somewhat Access: Switzerland, Germany Do Not Have Easy Access: Italy, Hungary, India, United States, Switzerland, Chile, Finland, Mexico, Canada, Dominican Republic, Peru, Great Britain, Singapore Do Not Have Access at All: Kenya, Great Britain, Colombia, Philippines, Iran, Bulgaria

FAMILY/CAREGIVER 4 GOVERNMENT 0 INSURANCE COMPANY 0 PHARMACY 0 OTHER PATIENTS 16 INTERNET 22 PATIENT ADVOCACY GROUPS 20 PHYSICIANS 23 0 5 10 15 20 25

NOT AT ALL SIGNIFICANT 0 NOT VERY SIGNIFICANT 4 SOMEWHAT SIGNIFICANT 13 VERY SIGNIFICANT 10 0 2 4 6 8 10 12 14

Very Significant: Italy, Hungary, Guatemala, Chile, Israel, Finland, Brazil, Dominican Republic, Colombia Somewhat Significant: US, Kenya, India, Switzerland, Germany, China, Mexico, Canada, Peru, Philippines, Pakistan Not Very Significant: US, Great Britain, Japan Not At All Significant: N/A

make dissemination of information to patients a priority the next step is to target these countries for improvement become a priority of the patient advocacy community share successful strategies and pair these groups with others that can use help

Image credit: http://www.sekari.com/google-tests-split-view-screen-for-different-languages/